Indaptus Therapeutics (INDP) executive compensation, 2026 proxy

Jeffrey A. Meckler, Co-Chief Executive Officer, was paid $2.2M in 2025, up 90% from $1.2M the year before.

Filed
January 21, 2026
Annual meeting
February 26, 2026
Pay year
2025
Named executives
4
CEO total pay
$2.2M+90% vs prior year
2025 CEO Total Compensation
$2,197,171Increased from prior year
CEO Target Bonus Percentage
50%Based on base salary
Modification Shares for CEO
216,617Common stock in lieu of cash

How Meckler was paid

$2.2M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary21%Non-equity incentive14%All other compensation66%

Named executive officers

ExecutiveTotal
Jeffrey A. MecklerCo-Chief Executive Officer$2,197,171
David E. LazarCo-Chief Executive Officer—
Walt A. Linscott, Esq.Chief Operating Officer$1,953,870
Michael J. NewmanChief Science Officer$1,691,286

What changed and why

  • $2.2MCEO total compensation increased to $2,197,171 in 2025 from $1,157,217 in 2024.
  • Named executive officers entered into modification agreements waiving severance and future annual bonuses.
  • Executives received cash and equity settlement payments under the modification agreements.
  • No option grants were made to named executive officers during 2025.
  • David E. Lazar was appointed as Co-Chief Executive Officer on December 23, 2025.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.